Next-Generation Phenotypic Screening
- 30 June 2016
- journal article
- review article
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 8 (11) , 1331-1347
Abstract
Phenotypic drug discovery (PDD) strategies are defined by screening and selection of hit or lead compounds based on quantifiable phenotypic endpoints without prior knowledge of the drug target. We outline the challenges associated with traditional phenotypic screening strategies and propose solutions and new opportunities to be gained by adopting modern PDD technologies. We highlight both historical and recent examples of approved drugs and new drug candidates discovered by modern phenotypic screening. Finally, we offer a prospective view of a new era of PDD underpinned by a wealth of technology advances in the areas of in vitro model development, high-content imaging and image informatics, mechanism-of-action profiling and target deconvolution.Keywords
This publication has 95 references indexed in Scilit:
- Phenotypic screening in cancer drug discovery — past, present and futureNature Reviews Drug Discovery, 2014
- The discovery of first-in-class drugs: origins and evolutionNature Reviews Drug Discovery, 2014
- Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional ApproachesSLAS Discovery, 2013
- Combining imaging and pathway profiling: an alternative approach to cancer drug discoveryDrug Discovery Today, 2012
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- Fully automated cellular-resolution vertebrate screening platform with parallel animal processingLab on a Chip, 2011
- How were new medicines discovered?Nature Reviews Drug Discovery, 2011
- Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug DiscoveryPharmaceutics, 2011
- The beautiful cell: high-content screening in drug discoveryAnalytical and Bioanalytical Chemistry, 2010
- Target-based drug discovery: is something wrong?Drug Discovery Today, 2005